For the Inventor, By the Inventor

Enter assignee name

San Francisco, CA, United States of America

Medivation Technologies, Inc.

USPTO Granted Patents = 63

% Expired Patents = 74.6

CIPO Patents = 2

EPO Patents = 9

Forward Citations = 723

Loading Chart...

Loading Chart...

40 inventors (with patents filed for the assignee):

Sarvajit Chakravarty (54 out of 87 patents)

Rajendra Parasmal Jain (45 out of 48 patents)

Andrew Asher Protter (26 out of 35 patents)

4. David T Hung (19 out of 42 patents)

5. Roopa Rai (8 out of 22 patents)

6. Sundeep Dugar (8 out of 80 patents)

7. Bing Wang (7 out of 64 patents)

8. Barry Patrick Hart (7 out of 10 patents)

9. Michael J Green (7 out of 61 patents)

10. Daniel T Chu (7 out of 98 patents)

11. Son Minh Pham (6 out of 26 patents)

12. Brahmam Pujala (6 out of 22 patents)

13. Bharat Uttam Shinde (5 out of 5 patents)

14. Anjan Kumar Nayak (4 out of 11 patents)

15. Sreekanth A Ramachandran (4 out of 8 patents)

Core Competencies:

Heterocyclic Compounds

Dihydropyridophthalazinone

Poly(ADP-Ribose)Polymerase

Diabetes Treatments

Hypertension Treatments

Fused Pyrimidine

Pyrido Indoles

Bridged Compounds

Tetracyclic Compounds

Azepino Indoles

Crystalline Compounds

Phenylcarbamoyl Compounds

63 patents: Sort by Forward Citations

1. 11702401 - Compounds and methods of use (2023-07-18),

2. 11364241 - Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) (2022-06-21),

3. 11053216 - Compounds and methods of use (2021-07-06),

4. 10780088 - Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) (2020-09-22),

5. 10543209 - Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) (2020-01-28),

6. 10501436 - Compounds and methods of use (2019-12-10),

7. 10493078 - Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) for use in treatment of diseases associated with a PTEN deficiency (2019-12-03),

8. 10189837 - Crystalline (8S,9R)-5-fluoro-8-(4-fluorophenyl)-9-(1-methyl-1H-1,2,4-triazol-5-yl)-8,9-dihydro-2H-pyrido[4,3,2-de]phthalazin-3(7H)-one tosylate salt (2019-01-29),

9. 10189826 - Heterocyclic compounds and methods of use (2019-01-29),

10. 10183015 - Heterocyclic compounds and methods of use (2019-01-22),

11. 10030004 - Compounds and methods of use (2018-07-24),

12. 9926303 - Processes of synthesizing dihydropyridophthalazinone derivatives (2018-03-27),

13. 9820985 - Dihydropyridophthalazinone inhibitors of poly(ADP-ribose)polymerase (PARP) (2017-11-21),

14. 9670172 - Heterocyclic compounds and methods of use (2017-06-06),

15. 9580425 - Pyrido[3,4-b] indoles and methods of use (2017-02-28),

Company Overview

Medivation Technologies, Inc., based in San Francisco, CA, specializes in the development of innovative therapeutic solutions focusing on heterocyclic compounds. The company is engaged in advanced research in areas such as dihydropyridophthalazinone and poly(ADP-ribose) polymerase, targeting treatments for diabetes and hypertension. With a strong emphasis on fused pyrimidine, pyrido indoles, and bridged compounds, Medivation is committed to addressing significant health challenges through its cutting-edge technology and research initiatives.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 20 2026

63 Patents

#80 in San Francisco, CA

#1,347 in California

#5,767 in US

#11,640 in the World

San Francisco, CA, United States of America

Medivation Technologies, Inc.

Forward Citations = 723

40 inventors:

Sarvajit Chakravarty (54 out of 87 patents)

Rajendra Parasmal Jain (45 out of 48 patents)

Andrew Asher Protter (26 out of 35 patents)

4. David T Hung (19 out of 42 patents)

5. Roopa Rai (8 out of 22 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Medivation Technologies, Inc.. Retrieved from https://idiyas.com/company/medivation-technologies

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…